vs
莫德纳（MRNA）与Rollins, Inc.（ROL）财务数据对比。点击上方公司名可切换其他公司
莫德纳的季度营收约是Rollins, Inc.的1.1倍（$1.0B vs $906.4M），Rollins, Inc.净利率更高（11.9% vs -19.7%，领先31.6%），Rollins, Inc.同比增速更快（10.2% vs -45.4%），Rollins, Inc.自由现金流更多（$111.2M vs $-880.0M），过去两年Rollins, Inc.的营收复合增速更高（0.8% vs -45.0%）
莫德纳是一家总部位于美国马萨诸塞州剑桥市的生物制药企业，深耕RNA治疗领域，核心业务聚焦mRNA疫苗研发。其疫苗通过信使RNA（mRNA）分子拷贝传递蛋白合成指令以触发人体免疫反应，公司名称由“修饰”“RNA”与“现代”三个词组合而来。
Rollins, Inc.是北美知名虫害防治服务商，面向住宅及商业客户提供专业防控服务。公司依托Orkin、HomeTeam Pest Defense等多家全资子公司布局全球业务，覆盖北美、英国等市场，在民用及商用虫害治理领域具备深厚的行业积累与品牌优势。
MRNA vs ROL — 直观对比
营收规模更大
MRNA
是对方的1.1倍
$906.4M
营收增速更快
ROL
高出55.6%
-45.4%
净利率更高
ROL
高出31.6%
-19.7%
自由现金流更多
ROL
多$991.2M
$-880.0M
两年增速更快
ROL
近两年复合增速
-45.0%
损益表 — Q3 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $1.0B | $906.4M |
| 净利润 | $-200.0M | $107.8M |
| 毛利率 | 79.6% | — |
| 营业利润率 | -25.6% | 16.1% |
| 净利率 | -19.7% | 11.9% |
| 营收同比 | -45.4% | 10.2% |
| 净利润同比 | -1638.5% | 2.5% |
| 每股收益（稀释后） | $-0.51 | $0.22 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MRNAROL
| Q1 26 | — | $906.4M | ||
| Q4 25 | — | $912.9M | ||
| Q3 25 | $1.0B | $1.0B | ||
| Q2 25 | — | $999.5M | ||
| Q1 25 | — | $822.5M | ||
| Q4 24 | $966.0M | $832.2M | ||
| Q3 24 | $1.9B | $916.3M | ||
| Q2 24 | — | $891.9M |
净利润MRNAROL
| Q1 26 | — | $107.8M | ||
| Q4 25 | — | $116.4M | ||
| Q3 25 | $-200.0M | $163.5M | ||
| Q2 25 | — | $141.5M | ||
| Q1 25 | — | $105.2M | ||
| Q4 24 | $-1.1B | $105.7M | ||
| Q3 24 | $13.0M | $136.9M | ||
| Q2 24 | — | $129.4M |
毛利率MRNAROL
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 79.6% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 23.5% | — | ||
| Q3 24 | 72.4% | — | ||
| Q2 24 | — | — |
营业利润率MRNAROL
| Q1 26 | — | 16.1% | ||
| Q4 25 | — | 17.5% | ||
| Q3 25 | -25.6% | 21.9% | ||
| Q2 25 | — | 19.8% | ||
| Q1 25 | — | 17.3% | ||
| Q4 24 | -129.0% | 18.1% | ||
| Q3 24 | -3.8% | 20.9% | ||
| Q2 24 | — | 20.4% |
净利率MRNAROL
| Q1 26 | — | 11.9% | ||
| Q4 25 | — | 12.8% | ||
| Q3 25 | -19.7% | 15.9% | ||
| Q2 25 | — | 14.2% | ||
| Q1 25 | — | 12.8% | ||
| Q4 24 | -115.9% | 12.7% | ||
| Q3 24 | 0.7% | 14.9% | ||
| Q2 24 | — | 14.5% |
每股收益（稀释后）MRNAROL
| Q1 26 | — | $0.22 | ||
| Q4 25 | — | $0.24 | ||
| Q3 25 | $-0.51 | $0.34 | ||
| Q2 25 | — | $0.29 | ||
| Q1 25 | — | $0.22 | ||
| Q4 24 | $-2.91 | $0.22 | ||
| Q3 24 | $0.03 | $0.28 | ||
| Q2 24 | — | $0.27 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.1B | $116.5M |
| 总债务越低越好 | — | $650.6M |
| 股东权益账面价值 | $9.3B | $1.4B |
| 总资产 | $12.1B | $3.2B |
| 负债/权益比越低杠杆越低 | — | 0.47× |
8季度趋势，按日历期对齐
现金及短期投资MRNAROL
| Q1 26 | — | $116.5M | ||
| Q4 25 | — | $100.0M | ||
| Q3 25 | $1.1B | $127.4M | ||
| Q2 25 | — | $123.0M | ||
| Q1 25 | — | $201.2M | ||
| Q4 24 | $1.9B | $89.6M | ||
| Q3 24 | $1.6B | $95.3M | ||
| Q2 24 | — | $106.7M |
总债务MRNAROL
| Q1 26 | — | $650.6M | ||
| Q4 25 | — | $486.1M | ||
| Q3 25 | — | $485.7M | ||
| Q2 25 | — | $485.3M | ||
| Q1 25 | — | $485.5M | ||
| Q4 24 | — | $395.3M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
股东权益MRNAROL
| Q1 26 | — | $1.4B | ||
| Q4 25 | — | $1.4B | ||
| Q3 25 | $9.3B | $1.5B | ||
| Q2 25 | — | $1.4B | ||
| Q1 25 | — | $1.4B | ||
| Q4 24 | $10.9B | $1.3B | ||
| Q3 24 | $11.9B | $1.3B | ||
| Q2 24 | — | $1.2B |
总资产MRNAROL
| Q1 26 | — | $3.2B | ||
| Q4 25 | — | $3.1B | ||
| Q3 25 | $12.1B | $3.2B | ||
| Q2 25 | — | $3.2B | ||
| Q1 25 | — | $2.9B | ||
| Q4 24 | $14.1B | $2.8B | ||
| Q3 24 | $15.8B | $2.8B | ||
| Q2 24 | — | $2.8B |
负债/权益比MRNAROL
| Q1 26 | — | 0.47× | ||
| Q4 25 | — | 0.35× | ||
| Q3 25 | — | 0.32× | ||
| Q2 25 | — | 0.34× | ||
| Q1 25 | — | 0.36× | ||
| Q4 24 | — | 0.30× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-847.0M | $118.4M |
| 自由现金流经营现金流 - 资本支出 | $-880.0M | $111.2M |
| 自由现金流率自由现金流/营收 | -86.6% | 12.3% |
| 资本支出强度资本支出/营收 | 3.2% | 0.8% |
| 现金转化率经营现金流/净利润 | — | 1.10× |
| 过去12个月自由现金流最近4个季度 | $-1.9B | $621.1M |
8季度趋势，按日历期对齐
经营现金流MRNAROL
| Q1 26 | — | $118.4M | ||
| Q4 25 | — | $164.7M | ||
| Q3 25 | $-847.0M | $191.3M | ||
| Q2 25 | — | $175.1M | ||
| Q1 25 | — | $146.9M | ||
| Q4 24 | $825.0M | $188.2M | ||
| Q3 24 | $-1.6B | $146.9M | ||
| Q2 24 | — | $145.1M |
自由现金流MRNAROL
| Q1 26 | — | $111.2M | ||
| Q4 25 | — | $159.0M | ||
| Q3 25 | $-880.0M | $182.8M | ||
| Q2 25 | — | $168.0M | ||
| Q1 25 | — | $140.1M | ||
| Q4 24 | $303.0M | $184.0M | ||
| Q3 24 | $-1.7B | $139.4M | ||
| Q2 24 | — | $136.4M |
自由现金流率MRNAROL
| Q1 26 | — | 12.3% | ||
| Q4 25 | — | 17.4% | ||
| Q3 25 | -86.6% | 17.8% | ||
| Q2 25 | — | 16.8% | ||
| Q1 25 | — | 17.0% | ||
| Q4 24 | 31.4% | 22.1% | ||
| Q3 24 | -92.2% | 15.2% | ||
| Q2 24 | — | 15.3% |
资本支出强度MRNAROL
| Q1 26 | — | 0.8% | ||
| Q4 25 | — | 0.6% | ||
| Q3 25 | 3.2% | 0.8% | ||
| Q2 25 | — | 0.7% | ||
| Q1 25 | — | 0.8% | ||
| Q4 24 | 54.0% | 0.5% | ||
| Q3 24 | 8.1% | 0.8% | ||
| Q2 24 | — | 1.0% |
现金转化率MRNAROL
| Q1 26 | — | 1.10× | ||
| Q4 25 | — | 1.41× | ||
| Q3 25 | — | 1.17× | ||
| Q2 25 | — | 1.24× | ||
| Q1 25 | — | 1.40× | ||
| Q4 24 | — | 1.78× | ||
| Q3 24 | -120.46× | 1.07× | ||
| Q2 24 | — | 1.12× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
MRNA
| COVID19 | $971.0M | 96% |
| Other Revenue | $20.0M | 2% |
| Grant | $14.0M | 1% |
| Collaboration Arrangement Including Arrangements With Affiliate | $7.0M | 1% |
| License And Royalty | $2.0M | 0% |
ROL
暂无分部数据
